Canadian producer Aurora Cannabis loses another CA$1 billion

Struggling cannabis producer Aurora Cannabis reported a net loss of 1 billion Canadian dollars ($770 million) for the three months ended March 31 on plunging sales of adult-use products, bringing its loss this year to CA$1.1 billion.

The latest CA$1 billion loss brings the Edmonton, Alberta-based company’s cumulative net losses since 2015 to roughly CA$5.3 billion.

Net Revenue in the third quarter fell to CA$50.1 million, down from CA$54 million in the same period a year earlier.

Aurora’s adjusted EBITDA loss widened to CA$12.3 million in the third quarter, compared with CA$9 million in second quarter 2022.

But it was an improvement from the CA$20.9 million adjusted EBITDA loss in the prior-year period.

Aurora’s recreational cannabis net revenue plunged 43% for the January-March period year-over-year to CA$10.4 million and a stunning 73% off a third-quarter high in 2020.

Dried cannabis sales fell to CA$8.6 million, down sharply from CA$14.8 million a year earlier.

In the three months ended March 31, 2022, sales of cannabis derivatives – oils, capsules, softgels, edibles and vaporizers – more than halved to CA$2.8 million, from CA$6.6 million in the same period last year.

Medical cannabis sales, on the other hand, were a bright spot for the company.

Aurora sold CA$39.3 million of medical cannabis in Canada and overseas, which is 8.3% higher year-over-year.

Aurora also announced it is ramping up its transformation strategy in an attempt to reach profitability in the first half of next year.

The company now says it has identified annualized cash savings worth CA$170 million, which includes the closure of its flagship Aurora Sky facility in Edmonton – previously announced to be operating at approximately 25% capacity.

Aurora idled most of the greenhouse last year and laid off 200 workers.

Aurora had spent years and at least CA$150 million building the structure.

Over the past nine months, Aurora has closed or sold facilities in Canada, Denmark and Uruguay.

“During Q3, we continued focusing on our global medical cannabis business because it is both defensive and stable, with cash gross margins that exceed 60%,” CEO Miguel Martin noted in Aurora’s earnings release.

“In terms of the Canadian adult-use market, we continue to adjust to current conditions, are excited for future contributions from the Thrive team, and are committed to a continuous stream of innovation, including advancing our premiumization strategy.”

(Martin’s “Thrive team” comment was a reference to Aurora’s recent acquisition of TerraFarma, the parent company of craft producer Thrive Cannabis.)

MJBizDaily Indoor Cultivation Buyers Guide – Now available!

Master the complexities of growing cannabis indoors with fundamental tips and guidance from experienced cultivation professionals.

Featured inside:

  • Best practices in cultivation facility design
  • Tips for mapping out a climate control system and purchasing components
  • Indoor cultivation buyers guide checklist
  • And more!

Another bright spot was the average net selling price.

The average net selling price of a gram of dried cannabis, excluding bulk sales, worked out to CA$5.41 in the quarter, up from CA$5 in the same quarter last year, and 20% higher than the previous quarter’s CA$4.52.

Aurora had CA$480.6 million of cash as of March 31, 2022.

Shares of Aurora trade as ACB on the Toronto Stock Exchange and the Nasdaq.